Last reviewed · How we verify
NCT05270824
Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma
Phase 3 trial testing radical surgery after neoadjuvant immunotherapy in Advanced Gastric Carcinoma in 120 participants. Not yet recruiting.
1 March 2024
Quick facts
| Lead sponsor | Fujian Medical University |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 March 2022 |
| Primary completion | 1 March 2024 |
| Estimated completion | 1 March 2027 |
Drugs / interventions tested
- radical surgery after neoadjuvant immunotherapy
- radical surgery after neoadjuvant chemotherapy
Conditions studied
- Advanced Gastric Carcinoma — all drugs for Advanced Gastric Carcinoma →
- CD8+ Tumor Infiltrating Lymphocytes — all drugs for CD8+ Tumor Infiltrating Lymphocytes →
- Neoadjuvant Immunotherapy — all drugs for Neoadjuvant Immunotherapy →
Sponsor
Fujian Medical University
Who can join
Adults 18 to 75, any sex, with Advanced Gastric Carcinoma or CD8+ Tumor Infiltrating Lymphocytes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Focusing on the clinical question of whether patients with advanced gastric cancer can benefit from immunotherapy, this project intends to detect the degree of CD8+ tumor-infiltrating lymphocyte infiltration in patients with advanced gastric cancer before and after receiving neoadjuvant combined immunotherapy and neoadjuvant therapy alone. To explore the evolving nature of tumor immune response before and after neoadjuvant therapy for gastric cancer, and quantitatively present it through chemical immunohistochemical techniques to achieve a more accurate diagnosis and treatment and improve the long-term efficacy of patients.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Increasing cure rates of solid tumors by immune checkpoint inhibitors.
Ma W, Xue R, Zhu Z, Farrukh H, et al · · 2023 · cited 84× · PMID 36647169 · DOI 10.1186/s40164-023-00372-8 -
Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy.
Yin X, Song Y, Deng W, Blake N, et al · · 2024 · cited 18× · PMID 39655071 · DOI 10.3389/fonc.2024.1483454 -
Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023).
Li YN, Xie B, Zhang Y, He MH, et al · · 2023 · cited 16× · PMID 37970478 · DOI 10.3748/wjg.v29.i40.5593
Verify or expand the search:
- PubMed search for NCT05270824
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Gastric Carcinoma
Currently open trials in the same condition.
- NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
- NCT06642857 — Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastr · recruiting
- NCT05969860 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer · Phase 2 · recruiting
- NCT05620732 — Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T · NA · recruiting
- NCT05226169 — Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC) · Phase 3 · recruiting
Other Fujian Medical University trials
Trials by the same sponsor.
- NCT07314203 — Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastr · Phase 3 · not yet recruiting
- NCT07491263 — Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Le · Phase 1 · not yet recruiting
- NCT07275034 — A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression · NA · not yet recruiting
- NCT07383909 — Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery · NA · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05270824 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University
- Last refreshed: 8 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05270824.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing